From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)
Cohort | 150 mg q8w n (%) | 150 mg q4w n (%) | 300 mg q8w n (%) | 300 mg q4w n (%) |
---|---|---|---|---|
crFMF (N=57) | 23 (40.4) | 20 (35.1) | 5 (8.8) | 9 (15.8) |
TRAPS (N=50) | 25 (50.0) | 5 (10.0) | 9 (18.0) | 11 (22.0) |
HIDS/MKD (N=64) | 14 (21.9) | 7 (10.9) | 11 (17.2) | 32 (50.0) |